Pozelimab - CISMeF

Preferred Label : Pozelimab;

NCIt synonyms : WHO 10945;

NCIt definition : A human immunoglobulin G4 (IgG4) monoclonal antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, pozelimab targets and binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). C5, a complement pathway protein, is expressed at high levels by the liver.;

UNII : 0JJ21K6L2I;

CAS number : 2096328-94-6;

Molecule name : REGN-3918; REGN 3918;

NCI Metathesaurus CUI : CL971674;

Details

Origin ID

C166423;

UMLS CUI

C5139913;

Currated CISMeF NLP mapping
- Pozelimab [SMS substance]
Manual BTNT mappings - CISMeF
- pozelimab [ATC Code]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
has_target
- Complement C5 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients